

EARLY TERMINATIONS GRANTED MARCH 1, 2019 THRU MARCH 31, 2019—Continued

20191014	G	Novacap Industries IV, L.P.; GHP Group, Inc.; Novacap Industries IV, L.P.
03/25/2019		
20191004	G	Blackbird HoldCo, Inc.; Irving Place Capital Partners III SPV, L.P.; Blackbird HoldCo, Inc.
20191008	G	AP Drive, L.P.; EQT Infrastructure II Limited Partnership; AP Drive, L.P.
03/26/2019		
20191019	G	Concrete Pumping Holdings, Inc.; A. Keith Crawford and Melinda Crawford; Concrete Pumping Holdings, Inc.
03/29/2019		
20190912	G	George J. Pedersen; Kforce Inc.; George J. Pedersen.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC-5301, Washington, DC 20024, (202) 326-3100.

By direction of the Commission.

April J. Tabor,

Acting Secretary.

[FR Doc. 2019-08081 Filed 4-22-19; 8:45 am]

BILLING CODE 6750-01-P

FEDERAL TRADE COMMISSION

Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this

waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

EARLY TERMINATIONS GRANTED FEBRUARY 1, 2019 THRU FEBRUARY 28, 2019

02/04/2019		
20190275	G	The E.W. Scripps Company; EPI Group, LLC; The E.W. Scripps Company.
20190667	G	RLC Industries Co.; Potlatch Deltic Corporation; RLC Industries Co.
20190694	G	Christopher Grassi; Josue Christiano Gomes da Silva; Christopher Grassi.
20190707	G	Atlantic Regional Federal Credit Union; York County Federal Credit Union; Atlantic Regional Federal Credit Union.
20190712	G	Royal Dutch Shell plc; Landmark Industries; Royal Dutch Shell plc.
20190713	G	Landmark Industries Holdings, Ltd.; Landmark Industries; Landmark Industries Holdings, Ltd.
20190714	G	3i Group plc; Elliott Springer; 3i Group plc.
20190715	G	3i Group plc; Kevin Schneider; 3i Group plc.
20190721	G	ACI Group Holdings, Inc.; Sharpe Dry Goods Company, LLC; ACI Group Holdings, Inc.
20190730	G	John Paulson; Centerbridge Capital Partners II, L.P.; John Paulson.
20190737	G	SoftBank Vision Fund (AIV M1) L.P.; Automation Anywhere, Inc.; SoftBank Vision Fund (AIV M1) L.P.
20190741	G	KeyCorp; Gary Lieberman; KeyCorp.
20190760	G	Nordic Capital IX Beta, L.P.; Tulip Holding Limited; Nordic Capital IX Beta, L.P.
02/06/2019		
20190673	G	J.B. Hunt Transport Services, Inc.; Patrick Cory; J.B. Hunt Transport Services, Inc.
02/07/2019		
20190720	G	Henry Schein, Inc.; BW NAR AIV III, L.P.; Henry Schein, Inc.
02/08/2019		
20190488	G	Ari Ojalvo-Oner; 2288880 Ontario Limited; Ari Ojalvo-Oner.
20190561	G	CONMED Corporation; Filtration Group Equity LLC; CONMED Corporation.
20190751	G	The Baring Asia Private Equity Fund VI, L.P. 2; Pioneer Corporation; The Baring Asia Private Equity Fund VI, L.P. 2.
02/11/2019		
20190750	G	Reingold Geiger; Nemo Investor Aggregator, Ltd.; Reingold Geiger.
20190761	G	Zebra Technologies Corporation; Water Street Healthcare Partners III, L.P.; Zebra Technologies Corporation.
20190762	G	Michael Klein; Clarivate Analytics Plc; Michael Klein.

EARLY TERMINATIONS GRANTED FEBRUARY 1, 2019 THRU FEBRUARY 28, 2019—Continued

20190765	G	ShawCor Ltd.; ZCL Composites Inc.; ShawCor Ltd.
20190768	G	AE Industrial Partners Fund II, LP; OEP VI AIV Feeder (A), L.P.; AE Industrial Partners Fund II, LP.
20190770	G	NGL Energy Partners LP; DCP Midstream Partners, LP; NGL Energy Partners LP.
20190779	G	Starwood Energy Infrastructure Fund III U.S. Investor, L.P.; FirstEnergy Solutions Corp.; Starwood Energy Infrastructure Fund III U.S. Investor, L.P.
20190780	G	Steel Dynamics, Inc.; United Steel Supply, LLC; Steel Dynamics, Inc.
20190787	G	GTCR Fund XI/B LP; GTCR Fund XI/A LP; GTCR Fund XI/B LP.
20190789	G	AIPCF VI Indirect Investor AIV LP; General Electric Company; AIPCF VI Indirect Investor AIV LP.
20190794	G	Kirby Corporation; Arlen B. Cenac, Jr.; Kirby Corporation.
02/13/2019		
20190742	G	Elliott International Limited; Ebay Inc.; Elliott International Limited.
20190743	G	Elliott Associates, L.P.; Ebay Inc.; Elliott Associates, L.P.
02/14/2019		
20190738	G	Huntington Ingalls Industries, Inc.; Fulcrum IT Holdings, LLC; Huntington Ingalls Industries, Inc.
20190793	G	Tesla, Inc.; Maxwell Technologies, Inc.; Tesla, Inc.
02/15/2019		
20190798	G	Thoma Bravo Fund XII Global, L.P.; Rubicon Technology Partners (Cayman) L.P.; Thoma Bravo Fund XII Global, L.P.
20190800	G	FIC DBR Co-Invest Feeder, L.P.; Denham Oil & Gas Fund LP; FIC DBR Co-Invest Feeder, L.P.
20190801	G	AIF IX International Holdings, L.P. (Cayman); RPC Group Plc; AIF IX International Holdings, L.P. (Cayman).
20190803	G	Tyler Technologies, Inc.; Arlington Capital Partners II, LP; Tyler Technologies, Inc.
20190804	G	John Zimmer; Lyft, Inc.; John Zimmer.
20190805	G	Logan Green; Lyft, Inc.; Logan Green.
20190817	G	Chevron Corporation; Petroleo Brasileiro S.A.; Chevron Corporation.
20190826	G	Mr. Renrong Yu; Beijing OmniVision Technologies, Co. Ltd.; Mr. Renrong Yu.
02/19/2019		
20190764	G	Canaccord Genuity Group Inc.; Columbia Care LLC; Canaccord Genuity Group Inc.
02/20/2019		
20171983	G	Fresenius Medical Care AG & Co. KGaA; NxStage Medical, Inc.; Fresenius Medical Care AG & Co. KGaA.
02/21/2019		
20190748	G	Novartis AG; Ionis Pharmaceuticals, Inc.; Novartis AG.
02/22/2019		
20190775	G	Uniti Group Inc.; R. Otto Maly; Uniti Group Inc.
20190796	G	Aurobindo Pharma Limited; Spectrum Pharmaceuticals, Inc.; Aurobindo Pharma Limited.
20190799	G	Sumner Redstone; Pluto Inc.; Sumner Redstone.
02/25/2019		
20190797	G	Starboard Value and Opportunity Fund Ltd.; Bristol-Myers Squibb Company; Starboard Value and Opportunity Fund Ltd.
20190824	G	iAero Group Holdco LLC; New Swift Air Holdings, L.L.C.; iAero Group Holdco LLC.
20190827	G	Johnson & Johnson; MeiraGTx Holdings plc; Johnson & Johnson.
02/26/2019		
20190816	G	Sequoia Capital Global Growth Fund III—Endurance Partners; Aurora Innovation, Inc.; Sequoia Capital Global Growth Fund III—Endurance Partners.
20190823	G	Unite Parent Corp.; The Ultimate Software Group, Inc.; Unite Parent Corp.
20190837	G	KKR Asian Fund II Japan AIV L.P.; Thermo Fisher Scientific Inc.; KKR Asian Fund II Japan AIV L.P.
20190840	G	Wellspring Capital Partners VI, L.P.; BDCM Opportunity Fund II, L.P.; Wellspring Capital Partners VI, L.P.
20190842	G	SoftBank Vision Fund (AIV M2) L.P.; Fair Financial Corp.; SoftBank Vision Fund (AIV M2) L.P.
20190844	G	FLIR Systems, Inc.; Arlington Capital Partners III, L.P.; FLIR Systems, Inc.
20190850	G	Bain Capital Fund XII, L.P.; Rangers Renal Holdings LP; Bain Capital Fund XII, L.P.
20190851	G	Carousel Capital Partners V, L.P.; Sterling Group Partners III, L.P.; Carousel Capital Partners V, L.P.
20190852	G	LightBay Investment Partners LP; Levine Leichtman Capital Partners V, L.P.; LightBay Investment Partners LP.
20190857	G	One Rock Capital Partners II LP; Univar Inc.; One Rock Capital Partners II LP.
20190858	G	SPC Investment Co., L.P.; Patricia Bragg; SPC Investment Co., L.P.
20190859	G	PDS Parent, Inc.; Peachtree Parent, Inc.; PDS Parent, Inc.
20190862	G	RoundTable Healthcare Partners IV, L.P.; Moberg Pharma AB (publ); RoundTable Healthcare Partners IV, L.P.
20190865	G	Carlyle U.S. Equity Opportunity Fund II, L.P.; Cortec Group Fund V, L.P.; Carlyle U.S. Equity Opportunity Fund II, L.P.
20190867	G	Gryphon Partners V, L.P.; LLR Equity Partners IV, L.P.; Gryphon Partners V, L.P.

EARLY TERMINATIONS GRANTED FEBRUARY 1, 2019 THRU FEBRUARY 28, 2019—Continued

02/28/2019

20190825	G	Sentinel Capital Partners VI, L.P.; Benjamin Rutledge Wall II; Sentinel Capital Partners VI, L.P.
20190838	G	SoftBank Vision Fund (AIV M1) L.P.; Guardant Health, Inc.; SoftBank Vision Fund (AIV M1) L.P.
20190854	G	Carbonite, Inc.; TCV V, L.P.; Carbonite, Inc.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry, Program Support Specialist, Federal Trade Commission Premerger Notification Office, Bureau of Competition, Room CC-5301, Washington, DC 20024, (202) 326-3100.

By direction of the Commission.

April J. Tabor,

Acting Secretary.

[FR Doc. 2019-08080 Filed 4-22-19; 8:45 am]

BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[30-Day-19-19GW]

Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Agency for Toxic Substances and Disease Registry (ATSDR) has submitted the information collection request titled “Exposure Characterization and Measurements during Activities Conducted on Synthetic Turf Fields with Tire Crumb Rubber Infill” to the Office of Management and Budget (OMB) for review and approval. ATSDR previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on December 26, 2018 to obtain comments from the public and affected agencies. ATSDR received one comment related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

ATSDR will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639-7570 or send an email to omb@cdc.gov. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide written comments within 30 days of notice publication.

Proposed Project

Exposure Characterization and Measurements during Activities Conducted on Synthetic Turf Fields with Tire Crumb Rubber Infill—New—Agency for Toxic Substances and Disease Registry (ATSDR).

Background and Brief Description

Currently in the United States, there are more than 12,000 synthetic turf fields in use. While the Synthetic Turf Council has set guidelines for the content of crumb rubber used as infill in synthetic turf fields, manufacturing processes result in differences among types of crumb rubber. Additionally, the chemical composition may vary highly between different processes and source materials and may vary even within granules from the same origin.

From 2016–2018, the Agency for Toxic Substances and Disease Registry and the United States Environmental Protection Agency (ATSDR/US EPA) conducted pilot-scale research under the protocol titled “Collections Related to Synthetic Turf Fields with Crumb Rubber Infill,” and under two information collection requests (ICRs). Activity 1, under OMB Control No. 0923-0054 (expiration date 01/31/2017),

aimed to collect tire crumb rubber samples from 40 synthetic turf fields across the U.S. and from nine manufacturing facilities. Under OMB Control No. 0923-0058 (expiration date 08/13/2018), ATSDR/US EPA aimed to evaluate and characterize the human exposure potential to constituents in crumb rubber infill among a convenience sample of 60 field users (Activity 2) and to collect biological specimens (blood and urine) from 45 participants (Activity 3). Preliminary results from the pilot-scale study indicate the need for further investigation for a select group of chemicals to which field users may potentially be exposed.

ATSDR is requesting a new two-year PRA clearance to conduct a supplemental data collection, titled “Exposure Characterization and Measurements during Activities Conducted on Synthetic Turf Fields with Tire Crumb Rubber Infill”. The supplemental study will be a larger-scale assessment of exposure potential for individuals who use or play on synthetic turf fields with tire crumb rubber infill. The new ICR will address key limitations of the pilot-scale study, specifically, the small sample size, the lack of a comparison population, and an extremely short data collection period needed to meet early reporting requirements.

As before, the supplemental study will include field users who are persons who use synthetic turf fields with crumb rubber infill and who routinely perform activities that would result in a high level of contact to crumb rubber. The study will also include persons who play on natural grass fields to provide a comparison group.

The field users will be administered a detailed questionnaire about activity patterns on synthetic turf with crumb rubber infill; the questionnaire is largely the same as the one approved under OMB Control No. 0923-0058 with minor modifications. This instrument will be used to characterize exposure scenarios, including the nature and duration of potential exposures. Additionally, the questionnaire will include queries on potential external sources, such as dietary sources, to select chemicals.